GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

GRAIL, Inc.NASDAQ: GRAL

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $19.56M rose 38.0% year over year, ahead of the -90.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at -8.4% a year.

Context

  • Stock-based compensation amounted to 39.6% of revenue in FY2025, down 28.9 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +38.0% holds above the trailing-twelve-month pace of -90.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.56M+16.5% QoQ
Last fiscal yearDec 2025
$58.28M-32.3% YoY
LTMJun 2026
$5.97M-90.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.0%——
1 year-32.3%——
3-year CAGR-8.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
58.28M USD
Year-over-year change
-32.3%
4-year CAGR
-45.9%

Stock-Based Compensation vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 stock-based compensation of $5.97M is the smallest of the 10 companies compared; the peer median is $32.2M.
  • Its year-over-year change of -90.3% is the lowest of 9, against a peer median of -6.7%.
  • Stock-based compensation amounts to 3.6% of revenue for GRAL, versus a peer median of 9.1%.
GRAL Competitors Peer median
Stock-Based Compensation for GRAL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$381.42M +21.6%+32.5%14.1%
GHGuardant Health, Inc.LTM Sep 2026$210.96M +32.4%+20.6%16.5%
CSTLCastle Biosciences, Inc.LTM Mar 2026$44.49M -8.9%+8.1%13.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$35.7M +95.3%-8.5%7.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$25.54M ——6.4%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
GRALGRAIL, Inc.LTM Jun 2026$5.97M -90.3%-8.4%3.6%
Peer median (excluding GRAL) $32.2M-6.7%+7.4%9.1%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
Deferred Income Tax0(39.06M)(38.15M)(134.25M)(126.15M)
Stock-Based Compensation681.91M75.73M97.24M86.08M58.28M
Change in Working Capital21.59M(14.46M)7.72M(24.28M)12.41M
Accounts Receivables(6.88M)(8.68M)(1.38M)(3.37M)1.69M
Inventory(5.67M)(14.08M)(1.94M)3.07M2.62M
Accounts Payables1.3M2.34M2.89M(14.64M)(2.73M)
Other Working Capital32.85M5.95M8.16M(9.35M)10.84M
Other Non-Cash Items(201M)4.66B644.39M1.36B8.46M
Operating Cash Flow(688.13M)(561.31M)(595.8M)(577.16M)(299.01M)
Capital Expenditures(69.93M)(22.86M)(12.89M)(5.21M)(909K)
Acquisitions (Net)00000
Purchases of Investments000(545.8M)(1.31B)
Sales of Investments00001.22B
Other Investing Activities414.74M0000
Investing Cash Flow344.81M(22.86M)(12.89M)(551.01M)(85.05M)
Debt Repayment00000
Common Stock Issued5.98M000423.32M
Common Stock Repurchased(170K)0000
Dividends Paid00000
Other Financing Activities388.93M604.82M463.77M1.24B0
Financing Cash Flow394.74M604.82M463.77M1.24B423.32M
Effect of Forex Changes(194.61M)(511K)305K(62K)(147K)
Net Change in Cash(143.19M)20.13M(144.62M)116.07M39.12M
Free Cash Flow(758.06M)(584.17M)(608.69M)(582.36M)(299.01M)

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.